

DAFTAR PUSTAKA

1. Targher G, Byrne CD. From nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease: is it time for a change of terminology? *Hepatoma Res.* 2020;64(6):1-9.
2. Marchesini G, Day CP, Dufour JF, et al. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol.* 2016;64(6):1388-1402.
3. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. *J Hepatol.* 2020;73(1):202-209.
4. Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol.* 2019;4(5):389-398.
5. Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. *Hepatology.* 2006;44(4):865-873.
6. Niriella MA, Ediriweera DS, Kasturiratne A, et al. Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study. *PLoS One.* 2021;16(2):1-11.
7. Wu S, Wu F, Ding Y, Hou J, Bi J, Zhang Z. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis. *Sci Rep.* 2016;6(5):1-14.
8. Wong VWS, Wong GLH, Yeung JCL, et al. Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study. *Hepatology.* 2016;63(3):754-763.
9. Yuan Q, Wang H, Gao P, et al. Prevalence and Risk Factors of Metabolic-Associated Fatty Liver Disease among 73,566 Individuals in Beijing, China. *Int J Environ Res Public Health.* 2022;19(4):1-10.
10. Rachmatullah TF, Permatadewi CO, Hutami HT, Limantoro C, Purnomo, MD, PhD HD. Correlation between Non-Alcoholic Fatty Liver Disease (NAFLD) score (NFS) with Left Ventricular Mass Index (LVMI) in patients with . *J Biomed Transl Res.* 2021;7(2):79-85.



11. Bisaccia G, Ricci F, Mantini C, et al. Nonalcoholic fatty liver disease and cardiovascular disease phenotypes. *SAGE Open Med.* 2020;8:1-15.
12. Badmus OO, Hillhouse SA, Anderson CD, Hinds TD, Stec DE. Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways. *Clin Sci.* 2022;136(18):1347-1366.
13. Boccatonda A, Andreetto L, D'Ardes D, et al. From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications. *Biomedicines.* 2023;11(3):1-15.
14. Hasan I. Perlemakan Hati Non Alkoholik. In: Buku Ajar Ilmu Penyakit Dalam Jilid II Edisi VI. *Interna Publishing.* 2014:2000-2006.
15. Kerner A, Avizohar O, Sella R, et al. Association between elevated liver enzymes and C-reactive protein: Possible hepatic contribution to systemic inflammation in the metabolic syndrome. *Arterioscler Thromb Vasc Biol.* 2005;25(1):193-197.
16. Clare K, Dillon JF, Brennan PN. Reactive Oxygen Species and Oxidative Stress in the Pathogenesis of MAFLD. *J Clin Transl Hepatol.* 2022;10(5):939-946.
17. Eslam M, Sarin SK, Wong VWS, et al. The Asian Pacific Association for the Study of the Liver Clinical Practice Guidelines for the Diagnosis and Management of Metabolic Associated Fatty Liver Disease. *Hepatology International.* Springer India. 2020;14:889-919.
18. Han AL. Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease. *Diabetol Metab Syndr.* 2022;14(1):1-14.
19. Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease. *Dig Liver Dis.* 2010;42(7):503-508.
20. World Health Organization Expert Consultation. Appropriate body mass index for Asian populations and its implications. *Lancet.* 2004;363:157-163.
21. PERKENI. Pengelolaan dan Pengobatan Diabetes Melitus Tipe 2 Dewasa di Indonesia. *PB Perkeni.* 2019:1-113.
22. Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. *Hypertension.* 2020;75(6):1334-1357.
- NI. Pengelolaan Dislipidemia Di Indonesia 2021. *PB Perkeni.* 2021:1-61.



24. Gorczyca-Głowacka I, Wełnicki M, Mamcarz A, et al. Metabolic associated fatty liver disease and cardiovascular risk: The expert opinion of the Working Group on Cardiovascular Pharmacotherapy of the Polish Cardiac Society. *Kardiol Pol.* 2023;81(2):207-214.
25. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. *Eur J Prev Cardiol.* 2022;29(1):5-115.
26. Targher G, Byrne CD. Circulating Markers of Liver Function and Cardiovascular Disease Risk. *Arterioscler Thromb Vasc Biol.* 2015;35(11):2290-2296.
27. Dunn W, Angulo P, Younossi ZM, et al. Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population-based Cohort Study. *Am J Gastroenterol.* 2008;103(9):2263-2271.
28. Patil R, Sood GK. Non-alcoholic fatty liver disease and cardiovascular risk. *World J Gastrointest Pathophysiol.* 2017;8(2):51-58
29. Neumann FJ, Sechtem U, Banning AP, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J.* 2020;41(3):407-477.
30. Arslan U, Turkoglu S, Balcioglu S, et al. Association between nonalcoholic fatty liver disease and coronary artery disease. *Coron Artery Dis.* 2007;18:433-436.
31. Ramanathan S, Al Heidous M, Alkuwari M. Coronary Artery Disease-Reporting and Data System (CAD-RADS): strengths and limitations. *Clin Radiol.* 2019;74(6):411-417.
32. Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation.* 2022;145(3):18-114.
33. Pipitone RM, Ciccioli C, Infantino G, et al. MAFLD: a multisystem disease. *Ther Adv Endocrinol Metab.* 2023;14:1-23.



34. Otaki Y, Gransar H, Cheng VY, et al. Gender differences in the prevalence, severity, and composition of coronary artery disease in the young: A study of 1635 individuals undergoing coronary CT angiography from the prospective, multinational confirm registry. *Eur Heart J Cardiovasc Imaging*. 2015;16(5):490-499.
35. Nakazato R, Arsanjani R, Achenbach S, et al. Age-related risk of major adverse cardiac event risk and coronary artery disease extent and severity by coronary CT angiography: Results from 15 187 patients from the international multisite CONFIRM study. *Eur Heart J Cardiovasc Imaging*. 2014;15(5):586-594.
36. Açıkel M, Sunay S, Koplay M, Gündoğdu F, Karakelleoğlu Ş. Evaluation of ultrasonographic fatty liver and severity of coronary atherosclerosis, and obesity in patients undergoing coronary angiography. *Anadolu Kardiyol Derg*. 2009;9(4):273-279.
37. Lind L, Markstad H, Ahlström H, et al. Obesity is associated with coronary artery stenosis independently of metabolic risk factors: The population-based SCAPIS study. *Atherosclerosis*. 2022;362(4):1-10.
38. Ciardullo S, Grassi G, Mancina G, Perseghin G. Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis. *Eur J Gastroenterol Hepatol*. 2022;34(4):365-371.
39. Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. *Diabetes Care*. 2007;30(5):1212-1218.
40. Mahalle N, Garg M, Naik S, Kulkarni M. Study of pattern of dyslipidemia and its correlation with cardiovascular risk factors in patients with proven coronary artery disease. *Indian J Endocrinol Metab*. 2014;18(1):48-55.
41. Baharvand-Ahmadi B, Sharifi K, Namdari M. Prevalence of non-alcoholic fatty liver disease in patients with coronary artery disease. *ARYA Atheroscler*. 2016;12(4):201-205.
42. Toh JZK, Pan XH, Tay PWL, et al. A Meta-Analysis on the Global Prevalence, Factors and Screening of Coronary Heart Disease in Nonalcoholic Fatty Liver
Clin Gastroenterol Hepatol. 2022;20(11):2462-2473.



43. Gholoobi A, Gifani M, Akhlaghi S, et al. Relationship between the prevalence and severity of non-alcoholic fatty liver disease and coronary artery disease: Findings from a cross-sectional study of a referral center in northeast Iran. *JGH Open*. 2022;6(5):330-337.
44. Choi DH, Lee SJ, Kang CD, et al. Nonalcoholic fatty liver disease is associated with coronary artery disease in Koreans. *World J Gastroenterol*. 2013;19(38):6453-6457.
45. Assy N, Djibre A, Farah R, Grosovski M, Marmor A. Presence of coronary plaques in patients with nonalcoholic fatty liver disease. *Radiology*. 2010;254(2):393-400.
46. Kim D, Choi SY, Park EH, et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. *Hepatology*. 2012;56(2):605-613.

